Skip to main content
Springer logoLink to Springer
. 2023 May 29;45(6):1349–1358. doi: 10.1007/s11096-023-01592-y

Factors associated with underreporting of adverse drug reactions by patients: a systematic review

Catarina Costa 1, Patricia Abeijon 2, Daniela A Rodrigues 3,4, Adolfo Figueiras 5,6,7, Maria Teresa Herdeiro 8, Carla Torre 1,9,
PMCID: PMC10682061  PMID: 37247159

Abstract

Background

Spontaneous reporting is the most used method to monitor post-marketing safety information. Although patient involvement in spontaneous reporting has increased overtime, little is known about factors associated with patients’ adverse drug reaction (ADR) reporting.

Aim

To identify and assess the sociodemographic characteristics, attitudes and knowledge that influence spontaneous reporting and the reasons associated with ADR underreporting by patients.

Method

A systematic review was conducted according to PRISMA guidelines. A search on the MEDLINE and EMBASE scientific databases was performed to retrieve studies published between 1 January 2006 and 1 November 2022. Studies were included if they addressed knowledge and attitudes associated with ADR underreporting.

Results

A total of 2512 citations were identified, of which 13 studies were included. Sociodemographic characteristics were frequently identified with ADR reporting in 6 studies, being age (3/13) and level of education (3/13) the most often reported. Older age groups (2/13) and individuals with higher level of education (3/13) were more likely to report ADRs. Underreporting was shown to be motivated by reasons related to knowledge, attitudes, and excuses. Ignorance (10/13), complacency (6/13), and lethargy (6/13) were the most frequent reasons for not reporting.

Conclusion

This study highlighted the scarcity of research conducted with the aim of assessing ADR underreporting by patients. Knowledge, attitudes, and excuses were commonly observed in the decision to report ADRs. These motives are characteristics that can be changed; hence strategies must be designed to raise awareness, continually educate, and empower this population to change the paradigm of underreporting.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11096-023-01592-y.

Keywords: Adverse drug reactions, Pharmacovigilance, Spontaneous reporting, Underreporting

Impact statements

  • Approaches to increasing ADR reporting should consider the sociodemographic characteristics of patients, including the level of education.

  • Strategies to decrease ignorance, complacency, and lethargy seem to be necessary to address the lack of reporting culture of ADR by patients.

  • The continuous implementation of awareness campaigns and educational programs tailored to different knowledge levels, could increase the engagement, and encourage the active participation of patients.

  • More research is required to inform the public, enhance ADR reporting and to provide current evidence on the effectiveness of pharmacovigilance interventions in reporting practice.

Introduction

Adverse drug reactions (ADRs) are a significant and worldwide public health problem, being a frequent cause of increased mortality [15], morbidity [14], healthcare costs [59] and hospital admissions [3, 59]. Spontaneous reporting is the most widely used method in pharmacovigilance to monitor safety information after a drug has been marketed, and through the collection of administrative health data provides the largest volume of information [1, 10, 11].

Although in the early years of pharmacovigilance, reporting ADRs was restricted to healthcare professionals (HCPs), HCPs and patients can now report suspected ADRs to spontaneous reporting systems [12, 13]. In 2012, there was a major change at the European Commission level, with the publication of pharmacovigilance legislation: Directive 2010/84/EU and Regulation No 1235/2010 [14]. One of the major changes comprised the empowerment and emphasis given to citizens as an additional source of information, enabling them to directly report suspected ADRs [1517].

It is acknowledged that the type of information reported by patients and HCPs is different [18]. Patients’ reports provide new information, including more subjective and detailed symptom descriptions of how ADRs impact daily life. HCPs report more objective and clinically related information [19]. The information provided by both populations demonstrates a positive contribution to obtain a more complete and full knowledge of reported ADRs [15, 2022].

ADRs are significantly underreported worldwide, with estimates that more than 94% are not reported by HCPs [23]. Underreporting can delay the detection of safety signals, making it difficult to evaluate and quantify risk factors, and consequently, compromising the full knowledge of the drug safety profile [11, 23, 24]. Furthermore, although direct patient reporting has been increasing over time, the overall contribution is still very low, representing only 9% of the total reports in 2014 [19, 2528].

Little is known about factors associated with ADR reporting by patients; however, studies have been emerging in recent years. Identifying the main barriers is crucial to understand gaps and to design specific strategies that can positively impact the quantity and quality of ADR reports and ultimately increase the safety of medicines. One systematic review was performed in 2006 regarding patient reporting of suspected ADRs, however none of the included studies concerned spontaneous reporting [29]. More recently, a systematic review assessed the motives and/or barriers that influence patient reporting of ADRs [30]. Our review assessed the factors associated with underreporting of ADR, including sociodemographic characteristics, reasons, and attitudes (modelled using Inman’s seven deadly sins [3133]), as well methodological quality, thereby adding more information to the body of evidence. Together with previous reviews, this covers the entire period of direct patient reporting worldwide.

Aim

The purpose of this systematic review was to identify and assess the sociodemographic characteristics, attitudes and knowledge that influence spontaneous reporting, and the reasons associated with underreporting of ADRs by patients.

Method

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [34] and a research protocol was registered in PROSPERO network database (CRD42021227944).

Search strategy

A search of MEDLINE PubMed and EMBASE scientific databases was performed to retrieve articles published between 1 January 2006 and 1 November 2022, with final search conducted on 2 November 2022. The search strategy used was: (attitud* OR knowledge* OR barrier* OR facilitators*) AND (Adverse Drug Reaction Reporting Systems[MesH] OR Drug-Related Side Effects and Adverse Reactions[MeSH]) AND report* (Electronic supplement material 1). The references cited by the included studies were examined by manual search.

Eligibility criteria

Studies were considered eligible for inclusion if: (i) the target population were patients and/or consumers; (ii) written in English, French, Portuguese, or Spanish; (iii) aimed to assess factors (personal characteristics as well as the reasons) associated with ADR underreporting; (iv) addressed ADR reporting through spontaneous reporting. The studies included could be either observational or interventional as they comprised original data. However, in interventional studies only baseline data were collected.

Conference abstracts/proceedings, reviews, editorials, letters to the editor, comments, theses/dissertations, systematic reviews and/or meta-analysis were excluded. Studies in which the target population were HCPs and/or students, focused on a specific pathology or treatment, and performed through intensive monitoring schemes or clinical trials were also excluded. For studies with no access, the authors were contacted. Finally, studies that identified attitudes and knowledge but did not directly associate underreporting reasons were excluded.

All articles retrieved were independently screened by 2 reviewers (CC and PA or CC and DR), who conducted full-text analysis to assess suitability for inclusion. For any divergent decisions, a third reviewer (CT, TH or AF) acted as referee to reach consensus.

Risk of bias and quality assessment

Critical assessment of the quality and risk of bias of the included studies were assessed using the Appraisal tool for Cross-Sectional Studies (AXIS) [35]. This tool was created in 2016 to appraise reporting quality, study design quality and risk of bias. It consists of a 20-component questionnaire, in which 7 questions focus on assessing the quality of the reports, 7 on the study design, and the remaining 6 assess the possibility of bias in the study. Fifteen out of the twenty items cover the methods and results sections, which reveals the importance of these two sections for critical appraisal of this tool. Two reviewers (CC and PA or CC and DR) independently conducted the critical assessment for each study, and in case of disagreement, a third reviewer (CT, TH or AF) was responsible for resolving discrepancies.

Data extraction and synthesis

Data from the eligible studies were extracted based on Lopez-Gonzalez et al. [36]. Reasons for ADR underreporting were based on a list of 7 attitudes described as the “seven deadly sins” (i.e., complacency, diffidence, ignorance, indifference, lethargy, greed: financial incentives, fear and guilty). This list was proposed in 1976 and further amended in 1986 and in 1996 [3133]. Additionally, to update and complement this list, other reasons influencing ADR underreporting were added according to those described in the literature. Therefore, 4 categories were created: (i) attitudes relating to professional activities (e.g., financial incentives, legal aspects); (ii) problems associated with ADR-related knowledge and attitudes (e.g., fear, complacency, diffidence, indifference, ignorance, insecurity); (iii) excuses made by the individual (e.g., lethargy); and (iv) others (e.g., lack of feedback, ADR resolved, poor reporting system). All these categories are described in the Electronic supplement material 2.

The extraction was performed by 2 authors (CC and PA or CC and DR) independently and included: author (year of publication), country, study design, setting, study population, response rate, sample size, data source, personal characteristics associated to reporting and reasons for not reporting ADRs. In case of inconsistencies, a third reviewer (CT, TH or AF) made the final decision. If further information was needed the corresponding authors were contacted.

Data analysis

The characteristics of the included studies were assessed through a descriptive analysis with each reason of underreporting reported numerically as a percentage (i.e. either extracted directly from the study (one specific question for each reason) or calculated using the mean/median when more than one question within the same study was associated to the same reason category mentioned above).

Results

Study selection

A total of 2399 citations were obtained from MEDLINE PubMed (n = 2023) and EMBASE (n = 376). After screening titles and abstracts, 113 duplicate studies were removed, and 2286 citations potentially met the inclusion criteria. Since 9 studies were excluded due to inaccessibility of full-text, a total of 253 articles underwent to full-text analysis. This resulted in thirteen studies [3749] meeting the inclusion criteria and were included in the review (Fig. 1).

Fig. 1.

Fig. 1

PRISMA 2020 flow diagram summarizing the study selection process

Characteristics of selected studies

The general characteristics of included studies are presented in Table 1 and the main study findings in Table 2.

Table 1.

Characteristics of the included studies that assessed factors associated with adverse drug reactions underreporting by patients

Author (Year of publication) Country Study designb Setting Sample size Response rate (%) Data collection method Scale Quality assessment (score obtained/total score)c
Wang et al. (2022) [37] China Cross sectional Not mentioned 869 80.09% Directly administered Likert 17/20
Januskiene et al. (2021)a [38] Several countries Not mentioned Not mentioned 1138 Not applicable Internet Multiple choice; free text 14/20
Pillay et al. (2021) [39] South Africa Quantitative descriptive Not mentioned 206 Not applicable Internet Multiple choice; free text 18/20
Al Dweik et al. (2020) [40] Canada Qualitative Not mentioned 15 Not applicable Interview Free text 16/20
Kim et al. (2020) [41] South Korea Cross sectional Not mentioned 1000 100% Internet Likert 17/20
Adisa and Omitogun (2019)a [42] Nigeria Cross sectional Primary care 360 94.7% Interview Free text; multiple choice 19/20
Adisa et al. (2019) [43] Nigeria Cross sectional Hospital 1190 99.1% Interview; directly administered Free text; multiple choice 18/20
Jacobs et al. (2019) [44] Ghana Quantitative and qualitative Hospital; primary care; retail 572 100% Interview; Directly administered Not mentioned 17/20
Sabblah et al. (2017) [45] Ghana Cross sectional Retail 510 86.7% Interview Likert 15/20
Patsuree et al. (2016) [46] Thailand Cross sectional Hospital; primary care; retail 2400 81.8% Directly administered Likert, free text, visual analogue scale 15/20
Matos et al. (2015) [47] Portugal Descriptive-correlational study Retail 1337 81.1% Directly administered Likert 15/20
Robertson and Newby (2013) [48] Australia Cross sectional Not mentioned 4981 6% Internet Not mentioned 10/20
Fortnum et al. (2012) [49] United Kingdom Not mentioned Not mentioned 2028 6.5% Interview Not mentioned 9/20

aArticle with information on HCPs and patients, however only patient information was retrieved

bStudy designs as reported by the authors

cQuality of the studies was assessed using the Appraisal tool for Cross-Sectional Studies (AXIS)

Table 2.

Studies that assessed the sociodemographic characteristics and reasons associated with underreporting adverse drug reactions

Author (Year of publication) Sociodemographic characteristicsb Reasons for under-reporting adverse drug reactionsc
Complacency Ignorance Lethargy Others
Wang et al. (2022) [37] NR 72.58% 16.49% 10.71%
Januskiene et al. (2021)a [38] NR 23.99% 3.69%
Pillay et al. (2021) [39] NR 37.38% 17.00%
Al Dweik et al. (2020) [40] NR
Kim et al. (2020) [41] Sex, monthly income NR 71.30% NR 63.50%
Adisa and Omitogun (2019)a [42] Age 14.70% 27.40% NR NR
Adisa et al. (2019) [43] NR NR NR 15.40%
Jacobs et al. (2019) [44] Age, region NR NR
Sabblah et al. (2017) [45] Age, sex, level of education, profession/employment status 14.80% 10.80% 37.00%
Patsuree et al. (2016) [46] NR 70.40% 17.10% 42.90%
Matos et al. (2015) [47] Level of education 24.60% NR NR NR
Robertson and Newby (2013) [48] 35.60% NR 16.40% 26.40%
Fortnum et al. (2012) [49] Social grade, level of education 22.00% 16.20% 7.40% 14.80%

✔—In studies where the reasons were stated but whose numerical measures were not mentioned, the symbol ✔ was used

NR Not reported

aArticle with information on HCPs and patients, however only patient information was retrieved

bSociodemographic characteristics reported to be statistically significantly associated with ADR reporting

cThe total numerical percentage regarding each reason for underreporting ADRs within each study was either extracted directly from the study (one specific question for each reason) or calculated using the mean/median (i.e. when more than one question within the same study was associated to a certain reason)

Five studies were conducted in Africa [39, 4244, 50], 3 in Europe [38, 47, 49], 3 in Asia [37, 41, 46], 1 in Australia [48] and 1 in Canada [40]. Most of the studies (n = 8, 61.5%) were cross-sectional, with 2 [38, 47, 49] failing to report the study design.

Four studies [4447] were conducted in a retail/community pharmacy, followed by 3 studies [43, 44, 46] in hospital and 3 [42, 44, 46] in primary care.

The sample size ranged from 15 to 4981 subjects and the response rate from 6.0 to 100%, being above 50.0% in 8 of the studies. The study with the highest number of recruited subjects (n = 4981) had the lowest response rate (6.0%) [48].

Six studies were conducted through direct interviews, which were face-to-face [4245] or telephone calls [49] or both [40], 5 studies opted to directly administer the questionnaire on site [37, 43, 44, 46, 47] and 4 studies used a web-based survey [38, 39, 41, 48]. Two studies combined 2 different types of data collection methods [43, 44].

Likert scale was the most often used (n = 5) [37, 41, 4547]. The free text response was used in 6 studies [3840, 42, 43, 46], followed by multiple choice (n = 4) [38, 39, 42, 43], visual analog scale (VAS) (n = 1) [46], with 3 studies failing to report the type of scales used [44, 48, 49].

Quality assessment

Six studies [37, 39, 4144] met ≥ 17 AXIS criteria, and therefore were considered of high methodological quality and low susceptibility to bias. Five studies [38, 40, 4547] were evaluated as having a moderate level of methodological quality and risk of bias, and the remaining of low methodologically quality and high susceptibility to bias. In general, the criteria least met were sample size justification, selection process and measures to address non-responders. None of the studies included any description of non-responders (Electronic supplement material 3).

Sociodemographic characteristics

The two most prevalent factors associated with the act of reporting were the level of education (n = 3) and age (n = 3). Age did not reach consensus since 1 study [42] revealed that the younger population was more likely to report ADRs than older age groups, whereas 2 studies [44, 50] showed the opposite. In all studies, individuals with higher levels of education were more likely to report ADRs.

The remainder reported factors were sex [41, 45], region [44], monthly income [41], social grade [49] and profession/employment status [50]. Specifically, it was found that males [41, 45], subjects living in urban areas (vs rural areas) [44], with higher monthly income [41] and higher social grades [49] were associated with higher intention to report ADRs. Additionally, a significant association was found between private sector employees and self-employed subjects and the higher likelihood to report as compared to unemployed, student, government employee and retired people [50].

Reasons for underreporting ADRs

The reasons that influenced the reporting of ADRs by patients were restricted to four categories. Ignorance (n = 10; with values ranging between 10.8 and 72.6%) [3742, 4446, 49] about the identification/recognition of ADRs, the possibility and importance of reporting them, as well as not knowing the needed requirements to report. Complacency (n = 6; values ranging from 14.7 to 35.6%) [40, 42, 45, 4749] mostly related with the conviction that only safe drugs are on the market and that serious ADRs are well documented by the time the drug is marketed. Lethargy (n = 6; values ranging from 3.7 to 17.1%) [3748, 48, 49, 4981], with patients referring that ADR reporting is time-consuming, generates work and that they would do it if the process was easier. In this category, forgetfulness and procrastination were also mentioned, but at a lower frequency. Other reasons (n = 11) [3741, 4346, 48, 49] that made patients reluctant to report ADRs included: (i) responsibility for ‘reporting lies’ with HCPs, (ii) ADR resolved or already expected; (iii) stopped taking the medicine; (iv) absence or difficulty in communicating with the HCP (e.g. unsupportive physician, diminishing ADR importance, lack of guidance, feeling it has to be reported to a physician and not another HCP); (v) lack of feedback or action taken by the authorities regarding previously submitted reports; and (vi) being abroad. Two studies did not present descriptive statistics for their assessment [40, 44].

Discussion

Main findings

This review showed that sociodemographic characteristics were commonly observed with ADR reporting whereas knowledge, attitudes, and excuses were frequently identified with ADR underreporting by patients. This review also highlighted the scarcity of research conducted with the aim of assessing ADR underreporting by patients. Over the last 15 years, most of the studies were conducted in African countries, where the pharmacovigilance framework is weak and relatively new [51]. The individual case safety reports retrieved by African countries represents only < 1% of the global reports [52] and to overcome this, patient reporting initiatives have been developed [53]. Over the review period, only 3 studies were conducted in European countries, despite the permission to allow ADR reporting by patients since 2012. Australia was the first country to allow direct patient reporting (1964) [12, 13] and had last evaluated this topic in 2013. Although Canada, USA and New Zealand shortly followed Australia [12], only Canada recently conducted one study to assess reasons for ADR underreporting.

Strengths and weaknesses

Our review has some limitations. Firstly, a search for studies in grey literature was not carried out. However, we believe that our results would not be affected since studies with this type of objective are usually associated with academic institutions where the incentive and ambition for publication is higher. We decided not to include conference abstracts/proceedings and editorials as these materials often reflect preliminary analysis, and it is less likely that methods and results are described with the necessary detail for the purpose of our study. Moreover, the percentages associated with each barrier might be subject to bias as means/medians were calculated if two or more statements were grouped in the same category within the same study. Finally, we acknowledge that our systematic review is limited by the details that authors have reported. However, an assessment of quality was performed for all included studies. Despite these acknowledged limitations, we believe that our main findings are relevant, and the data collected are comprehensive to assess the factors associated with underreporting of ADRs, thereby adding information to the body of evidence.

Interpretation of study findings

Regarding sociodemographic characteristics, the age factor was not unanimous. One study showed that the younger population is more likely to report ADRs [42], as they are well informed and may be of their relatives who might be more susceptible to experience an ADR. Since this population is a consumer of technologies, they can have a great impact on both learning and information sharing [13, 54]. However, 2 studies [44, 45] reported quite the opposite, as expected given that age is a well-known predisposing factor for the occurrence of ADRs [55]. Concerning education levels, all 3 studies [45, 47, 49] revealed that individuals with higher levels of education were more likely to report ADRs, a finding which is in line with the literature [56, 57].

Reasons related to ignorance were widely reported as obstacles to ADR reporting. These reasons may be associated with the fact that they have never heard about pharmacovigilance and may not recognize its importance. This ignorance may also be described as poor knowledge dissemination given that reporting systems might be more aligned with HCPs than patients [58].

Complacency was another reported reason as patients might believe that an ADR is not serious enough, or that it is not necessary to report. Complacency and ignorance could be highly related to the belief that marketed drugs are well-documented and safe. Lethargy justifies statements about forgetfulness, procrastination, lack of time or interest to report, and difficulty filling out the report. Simplifying reporting, promoting easier access, and boosting strategies that demonstrate that it is neither burdensome nor a bureaucratic process can overcome this barrier.

Overall, previous studies conducted among HCPs showed a wider spectrum of reasons for underreporting: fear, indifference, diffidence, ignorance, complacency, insecurity, unavailability of the reporting form, lethargy, ambition, and financial reimbursement [36, 42, 5965]. The discrepancy in the number of reasons given by HCPs and patients for underreporting may be associated with their different levels of knowledge concerning pharmacovigilance.

As in our review, patient-HCP communication problems have been identified in other studies [20, 6668] and might explain the reported barriers given by HCPs [62, 6979] concerning the patients' lack of information to submit reports or even disapproval by HCPs to patient reporting [80]. This aspect could be improved by creating a patient-friendly environment, giving an openness to speak without embarrassment or fear of judgment, thus positively changing the patient-HCP relationship.

A previous systematic review identified additional reasons for not reporting such as postal mailing costs or the limitation of restricting reporting to telephone during working hours [30]. However, these barriers probably no longer apply given the alternative methods of reporting ADRs (e.g. on-line platforms, mobile apps), which do not have associated costs or time limitations [13]. Of note, countries with an online reporting system option were associated with higher patient reporting rates [28].

The lack of interventions for patients was highlighted in a systematic review [81] which comprised 28 studies conducted with the aim of assessing if interventions targeting HCPs and patients were effective in improving ADR reporting. Only 1 study targeted patients, highlighting the need to develop tailored interventions for this population.

Several altruistic and personal motives that encourage patients to report ADRs have been described, such as contributing to increase safety knowledge, the need to be heard and to prevent harm to other patients [45, 47, 57, 66]. Other motives reported were related to the severity of the ADR, asking for feedback, feeling uncomfortable sharing information with HCPs [36, 59, 60] or the fact that HCPs did not take the case seriously [43, 44, 47, 57].

From the methodological point of view, only 6 studies of our systematic review were considered of high quality and low susceptibility to bias, which emphasizes the need for improvement when conducting future studies. Most of the included studies used a convenience sample and representativeness may be lacking, leading to potential selection bias. Most studies did not present a denominator and although some studies attempted to address non-responder rates, none was completely successful.

Future research

There is an urgent need to develop and conduct high quality, intervention based studies in this population to optimize ADR reporting and to provide evidence of effectiveness. Different communication, educational and promotional strategies targeted to patients should be designed and implemented to overcome the potentially modifiable barriers. Training and dissemination related to online platforms with clear, simple, and interactive content could be an efficient option to overcome these barriers.

Conclusion

This review highlighted the scarcity of studies conducted with the aim of assessing the influencing factors of underreporting ADRs by patients.

Sociodemographic characteristics appear to influence spontaneous reporting, with age and level of education being the most frequently reported. Patients’ attitudes observed linked to underreporting included ignorance, complacency, lethargy. These can be improved through the implementation of awareness campaigns and theoretical/practical educational programs tailored to different knowledge levels. Increasing engagement and encouraging active participation of patients is needed to reverse the current paradigm of underreporting.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

The authors would like to acknowledge to Dr. Susana Henriques from the library of the Faculty of Medicine of the University of Lisbon.

Funding

Open access funding provided by FCT|FCCN (b-on).

Conflicts of interest

The authors have no conflicts of interests to declare.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Montané E, Santesmases J. Reacciones adversas a medicamentos. Med Clin. 2020;154(5):178–184. doi: 10.1016/j.medcli.2019.08.007. [DOI] [PubMed] [Google Scholar]
  • 2.Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. J Am Med Assoc. 1998;279(15):1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
  • 3.Bouvy JC, de Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–453. doi: 10.1007/s40264-015-0281-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly: a meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759–770. doi: 10.1007/s00228-017-2225-3. [DOI] [PubMed] [Google Scholar]
  • 5.European Comission. Strengthening pharmacovigilance to reduce adverse effects of medicines. Memo/08/782. 2008. Availabe at: https://ec.europa.eu/commission/presscorner/detail/de/MEMO_08_782. Accessed 04 Dec 2021.
  • 6.Meier F, Maas R, Sonst A, et al. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf. 2015;24(2):176–186. doi: 10.1002/pds.3663. [DOI] [PubMed] [Google Scholar]
  • 7.Hoonhout LHF, de Bruijne MC, Wagner C, et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf. 2010;33(10):853–864. doi: 10.2165/11536800-000000000-00000. [DOI] [PubMed] [Google Scholar]
  • 8.Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: authors’ reply. BMJ. 2004;329(7456):15–19. doi: 10.1136/bmj.329.7456.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681–695. doi: 10.1080/14740338.2018.1491547. [DOI] [PubMed] [Google Scholar]
  • 10.Alomar M, Tawfiq AM, Hassan N, et al. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:204209862093859. doi: 10.1177/2042098620938595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743–752. doi: 10.1007/s00228-008-0475-9. [DOI] [PubMed] [Google Scholar]
  • 12.Herxheimer A, Crombag R, Alves TL. Direct patient reporting of adverse drug reactions a fifteen-country survey & literature review. Health Action International (Europe). 2010. Availabe at: https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/10%20May%202010%20Report%20Direct%20Patient%20Reporting%20of%20ADRs.pdf. Accessed 19 Nov 2021.
  • 13.Valinciute-Jankauskiene A, Kubiliene L. Adverse drug reaction reporting by patients in 12 European countries. Int J Environ Res Public Health. 2021;18(4):1507. doi: 10.3390/ijerph18041507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.European Comission. Regulation (EU) no 1235/2010 of the European Parliament and of the Council. EU. 2010. Available at: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF. Accessed 08 Nov 2021.
  • 15.Borg JJ, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187–197. doi: 10.2165/11586620-000000000-00000. [DOI] [PubMed] [Google Scholar]
  • 16.Santoro A, Genov G, Spooner A, et al. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf. 2017;40(10):855–869. doi: 10.1007/s40264-017-0572-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Herdeiro MT, Ferreira M, Ribeiro-Vaz I, et al. O sistema Português de farmacovigilância. Acta Med Port. 2012;25(4):241–249. [PubMed] [Google Scholar]
  • 18.Sienkiewicz K, Burzyńska M, Rydlewska-Liszkowska I, et al. The importance of direct patient reporting of adverse drug reactions in the safety monitoring process. Int J Environ Res Public Health. 2022;19(1):413. doi: 10.3390/ijerph19010413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–246. doi: 10.1111/bcp.13098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rolfes L, van Hunsel F, Wilkes S, et al. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24(2):152–158. doi: 10.1002/pds.3687. [DOI] [PubMed] [Google Scholar]
  • 21.Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35(10):807–818. doi: 10.1007/BF03261977. [DOI] [PubMed] [Google Scholar]
  • 22.Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK “Yellow card scheme”: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234. doi: 10.3310/hta15200. [DOI] [PubMed] [Google Scholar]
  • 23.Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396. doi: 10.2165/00002018-200629050-00003. [DOI] [PubMed] [Google Scholar]
  • 24.Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–C44. doi: 10.1016/s0149-2918(98)80007-6. [DOI] [PubMed] [Google Scholar]
  • 25.European Medicines Agency. EMA Annual Report 2017: The European Medicines Agency’s contribution to science, medicines and health in 2017. Available at: https://www.ema.europa.eu/en/documents/annual-report/2017-annual-report-european-medicines-agency_en.pdf. Accessed 28 Nov 2021.
  • 26.European Medicines Agency. 2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/report/2020-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. Accessed 28 Nov 2021.
  • 27.Banovac M, Candore G, Slattery J, et al. Patient reporting in the EU: analysis of EudraVigilance data. Drug Saf. 2017;40(7):629–645. doi: 10.1007/s40264-017-0534-1. [DOI] [PubMed] [Google Scholar]
  • 28.Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–419. doi: 10.1007/s40264-014-0162-y. [DOI] [PubMed] [Google Scholar]
  • 29.Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–156. doi: 10.1111/j.1365-2125.2006.02746.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Al Dweik R, Stacey D, Kohen D, et al. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):875–883. doi: 10.1111/bcp.13159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Inman WHW. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol. 1996;41(5):434–435. [PubMed] [Google Scholar]
  • 32.Inman WHW, Weber JCT. The United Kingdom. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press Ltd; 1986. pp. 13–47.
  • 33.Inman WHW. Assessment of drug safety problems. In: Gent M, ShigmatsuI, editors. Epidemiological issues in reported drug-induced illnesses. Honolulu(ON): McMaster University Library Press; 1976. pp. 17–24
  • 34.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS) BMJ Open. 2016;6(12):e011458. doi: 10.1136/bmjopen-2016-011458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. doi: 10.2165/00002018-200932010-00002. [DOI] [PubMed] [Google Scholar]
  • 37.Wang N, Chen Y, Ren B, et al. A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China. BMC Health Serv Res. 2022;22(1):318. doi: 10.1186/s12913-022-07720-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Januskiene J, Segec A, Slattery J, et al. What are the patients’ and health care professionals’ understanding and behaviors towards adverse drug reaction reporting and additional monitoring? Pharmacoepidemiol Drug Saf. 2021;30(3):334–341. doi: 10.1002/pds.5162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pillay S, Mulubwa M, Viljoen M. Parental reporting of adverse drug reactions in South Africa: an online survey. Afr J Prim Health Care Fam Med. 2021;13(1):e1–e8. doi: 10.4102/phcfm.v13i1.2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Al Dweik R, Yaya S, Stacey D, et al. Patients’ experiences on adverse drug reactions reporting: a qualitative study. Eur J Clin Pharmacol. 2020;76(12):1723–1730. doi: 10.1007/s00228-020-02958-1. [DOI] [PubMed] [Google Scholar]
  • 41.Kim S, Yu YM, You M, et al. A cross-sectional survey of knowledge, attitude, and willingness to engage in spontaneous reporting of adverse drug reactions by Korean consumers. BMC Public Health. 2020;20(1):1527. doi: 10.1186/s12889-020-09635-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):926. doi: 10.1186/s12913-019-4775-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Adisa R, Adeniyi OR, Fakeye TO. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. Int J Clin Pharm. 2019;41(4):1062–1073. doi: 10.1007/s11096-019-00849-9. [DOI] [PubMed] [Google Scholar]
  • 44.Jacobs TG, Hilda Ampadu H, Hoekman J, et al. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health. 2018;18(1):1384. doi: 10.1186/s12889-018-6285-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sabblah GT, Darko DM, Mogtari H, et al. Patients’ perspectives on adverse drug reaction reporting in a developing country: a case study from Ghana. Drug Saf. 2017;40(10):911–921. doi: 10.1007/s40264-017-0563-9. [DOI] [PubMed] [Google Scholar]
  • 46.Patsuree A, Krska J, Jarernsiripornkul N. Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand. Expert Opin Drug Saf. 2016;15(3):287–295. doi: 10.1517/14740338.2016.1135127. [DOI] [PubMed] [Google Scholar]
  • 47.Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? A Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883–890. doi: 10.1007/s00228-015-1867-2. [DOI] [PubMed] [Google Scholar]
  • 48.Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–686. doi: 10.5694/mja13.10069. [DOI] [PubMed] [Google Scholar]
  • 49.Fortnum H, Lee AJ, Rupnik B, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161–165. doi: 10.1111/j.1365-2710.2011.01273.x. [DOI] [PubMed] [Google Scholar]
  • 50.Sabblah GT, Akweongo P, Darko D, et al. Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana. Ghana Med J. 2014;48(4):189–193. doi: 10.4314/gmj.v48i4.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Isah AO, Pal SN, Olsson S, et al. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34. doi: 10.1177/2042098611425695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Ampadu HH, Hoekman J, de Bruin ML, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–345. doi: 10.1007/s40264-015-0387-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Pharmacy and Poisons Board Kenya. Suspected adverse drug reaction reporting form. Available at: https://pv.pharmacyboardkenya.org/. Accessed 18 Sep 2022.
  • 54.Sloane R, Osanlou O, Lewis D, et al. Social media and pharmacovigilance: a review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80(4):910–920. doi: 10.1111/bcp.12717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Alomar MJ. Factors affecting the development of adverse drug reactions (review article) Saudi Pharm J. 2014;22(2):83–94. doi: 10.1016/j.jsps.2013.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hariraj V, Aziz Z. Patient reporting of adverse drug reactions (ADRs): survey of public awareness and predictors of confidence to report. Ther Innov Regul Sci. 2018;52(6):757–763. doi: 10.1177/2168479017745025. [DOI] [PubMed] [Google Scholar]
  • 57.Jarernsiripornkul N, Patsuree A, Krska J. Public confidence in ADR identification and their views on ADRreporting: mixed methods study. Eur J Clin Pharmacol. 2017;73(2):223–231. doi: 10.1007/s00228-016-2155-5. [DOI] [PubMed] [Google Scholar]
  • 58.Chapman E, Haby MM, Toma TS, et al. Knowledge translation strategies for dissemination with a focus on healthcare recipients: an overview of systematic reviews. Implement Sci. 2020;15(1):14. doi: 10.1186/s13012-020-0974-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Varallo FR, de Guimarães SOP, Abjaude SAR, et al. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739–747. doi: 10.1590/s0080-623420140000400023. [DOI] [PubMed] [Google Scholar]
  • 60.Hailu AD, Mohammed SA. Adverse drug reaction reporting in Ethiopia: systematic review. Biomed Res Int. 2020;2020:8569314. doi: 10.1155/2020/8569314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Nadew SS, Michael Beyene KG, Beza SW. Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia. PLoS ONE. 2020;15(1):e0227712. doi: 10.1371/journal.pone.0227712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Ergün Y, Ergün TB, Toker E, et al. Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital. Int Health. 2019;11(3):177–184. doi: 10.1093/inthealth/ihy073. [DOI] [PubMed] [Google Scholar]
  • 63.Seid MA, Kasahun AE, Mante BM, et al. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. Int J Clin Pharm. 2018;40(4):895–902. doi: 10.1007/s11096-018-0682-0. [DOI] [PubMed] [Google Scholar]
  • 64.Gidey K, Seifu M, Hailu BY, et al. Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study. BMJ Open. 2020;10(2):e034553. doi: 10.1136/bmjopen-2019-034553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Abubakar AR, Bin Nimbak N, Haque M. A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. J Appl Pharm Sci. 2014;4:117–127. [Google Scholar]
  • 66.Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806–822. doi: 10.1111/j.1365-2125.2011.03990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Golomb BA, McGraw JJ, Evans MA, et al. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669–675. doi: 10.2165/00002018-200730080-00003. [DOI] [PubMed] [Google Scholar]
  • 68.van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–1150. doi: 10.1007/s00228-010-0865-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Hajj A, Hallit S, Ramia E, et al. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. Curr Med Res Opin. 2018;34(1):149–156. doi: 10.1080/03007995.2017.1361916. [DOI] [PubMed] [Google Scholar]
  • 70.Stergiopoulos S, Brown CA, Felix T, et al. A Survey of adverse event reporting practices among us healthcare professionals. Drug Saf. 2016;39(11):1117–1127. doi: 10.1007/s40264-016-0455-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Elnour AA, Ahmed AD, Yousif MAE, et al. Awareness and reporting of adverse drug reactions among health care professionals in Sudan. Jt Comm J Qual Patient Saf. 2009;35(6):324–329. doi: 10.1016/s1553-7250(09)35046-1. [DOI] [PubMed] [Google Scholar]
  • 72.Vessal G, Mardani Z, Mollai M. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World and Sci. 2009;31(2):183–187. doi: 10.1007/s11096-008-9276-6. [DOI] [PubMed] [Google Scholar]
  • 73.Gossell-Williams M, Adebayo SA. The pharmwatch programme: challenges to engaging the community pharmacists in Jamaica. Pharm Pract. 2008;6(4):187–190. doi: 10.4321/s1886-36552008000400003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Hughes ML, Weiss M. Adverse drug reaction reporting by community pharmacists: the barriers and facilitators. Pharmacoepidemiol Drug Saf. 2019;28(12):1552–1559. doi: 10.1002/pds.4800. [DOI] [PubMed] [Google Scholar]
  • 75.Danekhu K, Shrestha S, Aryal S, et al. Health-care professionals’ knowledge and perception of adverse drug reaction reporting and pharmacovigilance in a tertiary care teaching hospital of Nepal. Hosp Pharm. 2021;56(3):178–186. doi: 10.1177/0018578719883796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Thompson A, Randall C, Howard J, et al. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK. J Clin Pharm Ther. 2019;44(1):78–83. doi: 10.1111/jcpt.12756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Cheema E, Haseeb A, Khan TM, et al. Barriers to reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom. Pharm Pract. 2017;15(3):931. doi: 10.18549/PharmPract.2017.03.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Abu Hammour K, El-Dahiyat F, Abu FR. Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. J Eval Clin Pract. 2017;23(3):608–613. doi: 10.1111/jep.12683. [DOI] [PubMed] [Google Scholar]
  • 79.Gavaza P, Brown CM, Khoza S. Texas pharmacists’ opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study. Pharm World Sci. 2010;32(5):651–657. doi: 10.1007/s11096-010-9420-y. [DOI] [PubMed] [Google Scholar]
  • 80.Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13(9):1143–1152. doi: 10.1111/j.1365-3156.2008.02119.x. [DOI] [PubMed] [Google Scholar]
  • 81.Paudyal V, Al-Hamid A, Bowen M, et al. Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(9):1173–1191. doi: 10.1080/14740338.2020.1807003. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from International Journal of Clinical Pharmacy are provided here courtesy of Springer

RESOURCES